H
Honeybear Biosciences
Biotech & Life Sciences · Taipei, Taiwan · Founded 2022
Antibody drug conjugation platform advancing novel cancer therapeutics globally MoreLess
HoneyBear Biosciences, Inc, established in 2021, is a Taiwan-based biotech company focused on the global pharmaceutical market. The company specializes in developing new antibody technologies aimed at delivering novel therapeutics to cancer patients. Utilizing its proprietary antibody drug conjugation platform, CoNectar, HoneyBear Biosciences is at the forefront of global drug development. The company's business model revolves around leveraging its powerful antibody engineering platforms to develop and commercialize novel Antibody Drug Conjugates (ADCs) through licensing and co-development partnerships with biotech and pharmaceutical companies. HoneyBear Biosciences aims to improve therapeutic outcomes for cancer patients by creating the next wave of effective anti-cancer medicines. The company serves biotech and pharmaceutical clients, operating in the global pharmaceutical market. Revenue is generated through partnerships and licensing agreements. The management team boasts diverse international experience in chemistry and biological sciences, combining innovative research with rigorous development expertise. Keywords: antibody, drug conjugation, cancer therapeutics, CoNectar, ADCs, licensing, partnerships, biotech, pharmaceutical, Taiwan.
Company overview
Honeybear Biosciences company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2022
- Headquarters
- Taipei, Taiwan
- Employees
- —
- Open positions
- None listed
- Dealroom signal
- 20.0
Valuation & funding
Honeybear Biosciences funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2026 | $20M | $80M | A*STAR | ↗ |
Growth signals
Honeybear Biosciences website traffic
Latest recorded traffic for Honeybear Biosciences is 210 monthly website visits, down 46.2% over the last three months.
Comparisons
Honeybear Biosciences compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 IgualfanOral IgA antibody research and development for microbiome control |
Tokyo, Japan | Operational | — | $2.4M | $9.5M |
 Shizhiyuan BiotechnologyInnovative monoclonal antibody drug development and manufacturing |
China | Operational | |||
 Neologics BioscienceClinical-stage immuno-modulating antibody therapeutics for cancer |
Changzhou, China | Operational | |||
 Shengshi JunlianAI-driven discovery and optimization of macromolecular drugs |
Chengdu, China | Operational | |||
 Appfinder TherapeuticsAntibody drug development using proprietary screening platforms |
Anyang-si, South Korea | Operational | |||
 Dualitas TherapeuticsBispecific antibody therapies for immune and inflammatory diseases |
South San Francisco, United States | Operational | |||
 Adcoris BioPharmaNext-generation antibody-drug conjugates for oncology |
China | Operational | |||
 Minghui PharmaceuticalLate-stage biopharma developing therapeutics for cancer and immunology |
Ningbo, China | Operational |
Talent graph
Honeybear Biosciences's talent
Source: Dealroom Talent Intelligence.
Investors
1 investor on Honeybear Biosciences's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Honeybear Biosciences has talent and traffic
In the news
Latest news about Honeybear Biosciences
Recent press, funding announcements, and product moves mentioning Honeybear Biosciences — open to read from the original sources.
Market sentiment
What the market is saying about Honeybear Biosciences
An AI-synthesized read of the highest-engagement posts about Honeybear Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Honeybear Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.